Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers-Reference-Cited by-同舟云学术

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers

Author:

Yap Desmond Y. H.¹²,Hai Jojo¹³,Lee Paul C. H.¹⁴,Zhou Xueying⁵,Lee Michael⁵,Zhang Yu⁵,Wang Meng⁵,Chen Xiaoxiang⁵

Affiliation:

1. Phase I Clinical Trials Centre The University of Hong Kong Hong Kong Hong Kong

2. Division of Nephrology Department of Medicine The University of Hong Kong Hong Kong Hong Kong

3. Division of Cardiology Department of Medicine The University of Hong Kong Hong Kong Hong Kong

4. Division of Endocrinology and Metabolism Department of Medicine The University of Hong Kong Hong Kong Hong Kong

5. Harbour Biomed, Inc. Shanghai China

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

Reference22 articles.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献